BioMarin Pharmaceutical Inc. (BMRN) Appoints Pioneer In Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., To Board Of Directors
3/21/2014 8:40:45 AM
SAN RAFAEL, Calif., March 21, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of Dennis J. Slamon, M.D., Ph.D., director of Clinical/Translational Research and director of the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center, to the company's board of directors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by